Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945193 | 0.94 | CYP3A4 (0.39) | CYP3A4ELANEKCNH2 | |
| SCHEMBL7936156 | 0.93 | CYP3A4 (0.40) | CYP3A4ELANEKCNH2 | |
| SCHEMBL7936109 | 0.93 | CYP3A4 (0.41) | CYP3A4ELANEKCNH2 | |
| SCHEMBL13337039 | 0.93 | CYP3A4 (0.41) | CYP3A4ELANEKCNH2 | |
| SCHEMBL13365388 | 0.93 | CYP3A4 (0.33) | CYP3A4CTSS | |
| SCHEMBL7936165 | 0.93 | CYP3A4 (0.48) | CYP3A4ELANEKCNH2 | |
| SCHEMBL7945074 | 0.93 | CYP3A4 (0.33) | CYP3A4CTSS | |
| SCHEMBL13365353 | 0.92 | CYP3A4 (0.35) | CYP3A4ELANEKCNH2KDM4E | |
| SCHEMBL7935885 | 0.87 | CTSS (0.33) | CYP3A4CTSS | |
| SCHEMBL7936167 | 0.87 | CYP3A4 (0.32) | CYP3A4CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CYP3A4 3754/4885ELANE 382/4885KCNH2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.